Research programme: insulin analogues - Jilin Sihuan Pharmaceutical/Chongqing Peg-Bio Biotechnology

Alternative Names: Recombinant insulin aspart; Recombinant insulin degludec; Recombinant regular insulin

Latest Information Update: 04 Apr 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Chongqing Peg-Bio Biotechnology
Developer Jilin Sihuan Pharmaceutical
Class Antihypercalcaemics; Insulins; Pancreatic hormones; Recombinant proteins
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Diabetes mellitus

Most Recent Events

04 Apr 2018 Preclinical development is ongoing in China (Sihuan Pharmaceutical pipeline, April 2018)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.